QQQ   289.58 (-0.54%)
AAPL   137.35 (-2.46%)
MSFT   253.14 (-0.37%)
FB   191.29 (-0.49%)
GOOGL   2,207.68 (-1.35%)
AMZN   2,146.38 (+0.19%)
TSLA   709.42 (-0.05%)
NVDA   171.24 (+1.10%)
BABA   87.69 (+0.44%)
NIO   16.66 (+5.24%)
AMD   96.67 (+0.41%)
CGC   5.87 (+5.01%)
MU   69.40 (-2.32%)
T   20.21 (-0.10%)
GE   75.74 (+0.72%)
F   12.85 (+0.55%)
DIS   103.14 (-1.11%)
AMC   13.08 (+2.51%)
PFE   50.65 (+0.50%)
PYPL   81.28 (+5.31%)
NFLX   183.48 (+3.55%)
QQQ   289.58 (-0.54%)
AAPL   137.35 (-2.46%)
MSFT   253.14 (-0.37%)
FB   191.29 (-0.49%)
GOOGL   2,207.68 (-1.35%)
AMZN   2,146.38 (+0.19%)
TSLA   709.42 (-0.05%)
NVDA   171.24 (+1.10%)
BABA   87.69 (+0.44%)
NIO   16.66 (+5.24%)
AMD   96.67 (+0.41%)
CGC   5.87 (+5.01%)
MU   69.40 (-2.32%)
T   20.21 (-0.10%)
GE   75.74 (+0.72%)
F   12.85 (+0.55%)
DIS   103.14 (-1.11%)
AMC   13.08 (+2.51%)
PFE   50.65 (+0.50%)
PYPL   81.28 (+5.31%)
NFLX   183.48 (+3.55%)
QQQ   289.58 (-0.54%)
AAPL   137.35 (-2.46%)
MSFT   253.14 (-0.37%)
FB   191.29 (-0.49%)
GOOGL   2,207.68 (-1.35%)
AMZN   2,146.38 (+0.19%)
TSLA   709.42 (-0.05%)
NVDA   171.24 (+1.10%)
BABA   87.69 (+0.44%)
NIO   16.66 (+5.24%)
AMD   96.67 (+0.41%)
CGC   5.87 (+5.01%)
MU   69.40 (-2.32%)
T   20.21 (-0.10%)
GE   75.74 (+0.72%)
F   12.85 (+0.55%)
DIS   103.14 (-1.11%)
AMC   13.08 (+2.51%)
PFE   50.65 (+0.50%)
PYPL   81.28 (+5.31%)
NFLX   183.48 (+3.55%)
QQQ   289.58 (-0.54%)
AAPL   137.35 (-2.46%)
MSFT   253.14 (-0.37%)
FB   191.29 (-0.49%)
GOOGL   2,207.68 (-1.35%)
AMZN   2,146.38 (+0.19%)
TSLA   709.42 (-0.05%)
NVDA   171.24 (+1.10%)
BABA   87.69 (+0.44%)
NIO   16.66 (+5.24%)
AMD   96.67 (+0.41%)
CGC   5.87 (+5.01%)
MU   69.40 (-2.32%)
T   20.21 (-0.10%)
GE   75.74 (+0.72%)
F   12.85 (+0.55%)
DIS   103.14 (-1.11%)
AMC   13.08 (+2.51%)
PFE   50.65 (+0.50%)
PYPL   81.28 (+5.31%)
NFLX   183.48 (+3.55%)
NYSE:BVS

Bioventus (BVS) Stock Forecast, Price & News

$8.65
-0.06 (-0.69%)
(As of 05/19/2022 12:00 AM ET)
Add
Compare
Today's Range
$8.50
$8.91
50-Day Range
$7.49
$14.10
52-Week Range
$7.31
$19.94
Volume
181,224 shs
Average Volume
203,448 shs
Market Capitalization
$660.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.43
30 days | 90 days | 365 days | Advanced Chart
Receive BVS News and Ratings via Email

Sign-up to receive the latest news and ratings for Bioventus and its competitors with MarketBeat's FREE daily newsletter.

Bioventus logo

About Bioventus

Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Headlines

Bioventus (NYSE:BVS) Shares Gap Down to $8.61
Bioventus (BVS) to Release Quarterly Earnings on Tuesday
See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
1,200
Year Founded
N/A

Sales & Book Value

Annual Sales
$430.90 million
Cash Flow
$1.37 per share
Book Value
$6.83 per share

Profitability

Net Income
$19.38 million
Pretax Margin
-7.88%

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$660.76 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/10/2022
Today
5/19/2022
Next Earnings (Estimated)
8/09/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.00 out of 5 stars

Medical Sector

586th out of 1,418 stocks

Surgical & Medical Instruments Industry

68th out of 137 stocks

Analyst Opinion: 3.4Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -













Bioventus (NYSE:BVS) Frequently Asked Questions

Is Bioventus a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bioventus in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Bioventus stock.
View analyst ratings for Bioventus
or view top-rated stocks.

When is Bioventus' next earnings date?

Bioventus is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for Bioventus
.

How were Bioventus' earnings last quarter?

Bioventus Inc. (NYSE:BVS) released its quarterly earnings results on Tuesday, May, 10th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by $0.01. Bioventus had a negative net margin of 5.29% and a positive trailing twelve-month return on equity of 12.58%. During the same period in the previous year, the company posted ($0.02) EPS.
View Bioventus' earnings history
.

What guidance has Bioventus issued on next quarter's earnings?

Bioventus issued an update on its FY 2022 earnings guidance on Monday, May, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $545.00 million-$565.00 million, compared to the consensus revenue estimate of $553.75 million.

What price target have analysts set for BVS?

4 analysts have issued twelve-month price targets for Bioventus' stock. Their forecasts range from $17.00 to $30.00. On average, they anticipate Bioventus' stock price to reach $22.50 in the next year. This suggests a possible upside of 160.1% from the stock's current price.
View analysts' price targets for Bioventus
or view top-rated stocks among Wall Street analysts.

Who are Bioventus' key executives?
Bioventus' management team includes the following people:
  • Mr. Kenneth M. Reali, CEO & Director (Age 56, Pay $1.31M)
  • Ms. Alessandraa Pavesio, Sr. VP & Chief Science Officer (Age 55, Pay $634.95k)
  • Mr. Anthony D'Adamio, Sr. VP, Gen. Counsel & Corp. Sec. (Age 61, Pay $618.29k)
  • Mr. John Ernest Nosenzo, Sr. VP & Chief Commercial Officer (Age 64, Pay $907.28k)
  • Mr. Mark Singleton, Sr. VP, CFO & Principal Accounting Officer (Age 53)
  • Mr. Anthony James, VP of Operations and Quality
  • Mr. Miguel O. Beltran-Delgado, Sr. VP of Operations
  • Mr. David Crawford, VP of Investor Relations & Treasurer
  • Ms. Katrina J. Church, Sr. VP & Chief Compliance Officer (Age 60)
  • Mr. Jeff Welch, VP of Bus. Devel.
When did Bioventus IPO?

(BVS) raised $126 million in an initial public offering on Thursday, February 11th 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, Goldman Sachs and Canaccord Genuity acted as the underwriters for the IPO.

What is Bioventus' stock symbol?

Bioventus trades on the New York Stock Exchange (NYSE) under the ticker symbol "BVS."

Who are Bioventus' major shareholders?

Bioventus' stock is owned by many different institutional and retail investors. Top institutional shareholders include Royce & Associates LP (2.54%), BlackRock Inc. (2.33%), SV Health Investors LLC (1.95%), Nuance Investments LLC (1.77%), Vanguard Group Inc. (1.47%) and First Light Asset Management LLC (1.18%). Company insiders that own Bioventus stock include Anthony D'adamio, John Nosenzo, Katrina J Church and Kenneth Michael Reali.
View institutional ownership trends for Bioventus
.

Which major investors are selling Bioventus stock?

BVS stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Arrowstreet Capital Limited Partnership, SV Health Investors LLC, Rice Hall James & Associates LLC, Tamarack Advisers LP, JPMorgan Chase & Co., BlackRock Inc., and Northern Trust Corp. Company insiders that have sold Bioventus company stock in the last year include Anthony D'adamio, and John Nosenzo.
View insider buying and selling activity for Bioventus
or view top insider-selling stocks.

Which major investors are buying Bioventus stock?

BVS stock was bought by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, Wasatch Advisors Inc., Royce & Associates LP, Massachusetts Financial Services Co. MA, First Eagle Investment Management LLC, Nuance Investments LLC, Stephens Inc. AR, and Granite Point Capital Management L.P.. Company insiders that have bought Bioventus stock in the last two years include Katrina J Church, and Kenneth Michael Reali.
View insider buying and selling activity for Bioventus
or or view top insider-buying stocks.

How do I buy shares of Bioventus?

Shares of BVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bioventus' stock price today?

One share of BVS stock can currently be purchased for approximately $8.65.

How much money does Bioventus make?

Bioventus has a market capitalization of $660.76 million and generates $430.90 million in revenue each year. The company earns $19.38 million in net income (profit) each year or ($0.330010) on an earnings per share basis.

How many employees does Bioventus have?

Bioventus employs 1,200 workers across the globe.

What is Bioventus' official website?

The official website for Bioventus is www.bioventus.com.

How can I contact Bioventus?

Bioventus' mailing address is 4721 EMPEROR BOULEVARD SUITE 100, DURHAM NC, 27703. The company can be reached via phone at 919-474-6700 or via email at [email protected].

This page was last updated on 5/19/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.